What will Andrew Lansley’s appointment as Health Secretary mean for the Pharmaceutical and Healthcare markets?

The huge budget deficit means that efficiency savings and cuts within the NHS are inevitable.  Savings from medicines and healthcare products are easier to measure than other potential cost savings.  This could cause pressure to reduce the costs of these products and for the pharma/healthcare companies’ margins to be reduced further.  This could also effect reference pricing and influence companies’ decisions to invest in the UK.